FGF23 & Phosphate Disorders; Osteoporosis risk factors

OR43-1

The First Multi-Dose Trial of a Human Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) in Adults with X-Linked Hypophosphatemia (XLH)
Erik Allen Imel, Xiaoping Zhang, Mary Denise Ruppe, Thomas Joseph Weber, Mark Klausner, Takahiro Ito, Maria Vergeire, Jeffrey Humphrey, Francis H Glorieux, Anthony A Portale, Karl Insogna, Munro Peacock and Thomas O Carpenter

OR43-2

FGF23-Mediated Vitamin D Metabolism in Tumor-Induced Osteomalacia
Diala El-Maouche, Martin Kaufmann, Rachel I Gafni, Glenville Jones and Michael T. Collins

OR43-3

Fibroblast Growth Factor 23 Is Not Associated with Age-Related Changes in Phosphate Handling in Children
Deborah M Mitchell, Harald W Jueppner and Sherri-Ann M Burnett-Bowie

OR43-5

Increased Risk for Vertebral Fractures with Long-Term Observation in Mild Primary Hyperparathyroidism: Five Year Data from the Scandinavian Investigation of Primary Hyperparathyroidism (SIPH)
Karolina Lundstam, Mikael Hellström, Ansgar Heck, Kristin Godang, Marek Baranowski, Jan Erik Varhaug, Charlotte L Mollerup, Thord P Rosen, Jörgen Nordenström, Svante Jansson and Jens Bollerslev

OR43-6

Increased Bone Mineral Content in Patients with Congenital Generalized Lipodystrophy Is Unaffected By Metreleptin Replacement Therapy
John D. Christensen, Andreea O. Lungu, Elaine Cochran, Michael T. Collins, Rachel I Gafni, James C Reynolds, Phillip Gorden and Rebecca J. Brown